New Versa HD System Tops Elekta's Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum

Mon Apr 15, 2013 6:00am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130415:nPnCL93968

Latest Elekta linear accelerator sets benchmark in radiation oncology
versatility and capabilities
GENEVA,  April 15, 2013  /PRNewswire/ -- ESTRO Booth #3400 - Elekta will debut
its Versa HD system at the first major exhibition since the company introduced
the advanced linear accelerator globally on  March 1. The 2nd  ESTRO (European
Society for Radiotherapy and Oncology) Forum convenes  April 19-23  at the
Palexpo convention center in  Geneva.

Versa HD features high-precision beam shaping and tumor targeting, and the
versatility to deliver high-volume conventional therapies, plus the most
sophisticated linear accelerator-based treatments that require extreme targeting
precision. Elekta will also highlight its newly redesigned Flexitron®  remote
afterloading platform for brachytherapy designed to improve safety and
efficiency in the brachytherapy workflow, as well as new programs to simplify
the upgrade path from competitive oncology information systems (OIS) to MOSAIQ® 
OIS.

"We expect great interest in Versa HD at this year's ESTRO Forum," says  Ian
Alexander, Elekta's Executive Vice President Region Europe,  Africa,  Latin
America  and  Middle East. "Our most advanced linear accelerator was inspired by
the advent of new and more sophisticated therapies that are showing great
promise worldwide, combined with growing global cancer management challenges. It
truly represents a unique radiotherapy solution that will impact patient health
and quality of life."

"High-definition, high-speed beam shaping, combined with high dose rate delivery
makes Versa HD the ideal SBRT machine," says  Oscar Matzinger, M.D., radiation
oncologist at Centre Hospitalier Universitaire Vaudois (Lausanne,  Switzerland)
and Hopital Riviera (Vevey, Switzerland). "More and more radiotherapy patients
will be treated with SBRT, which now usually involves relatively long treatment
times. In treating lung cancer or liver metastases, the faster we can deliver
therapy the less chance for patient motion, and, in turn, the more precise
therapy will be. The High Dose Rate mode of Versa HD certainly facilitates
that."

Elekta will give live presentations of Versa HD at its exhibit booth (#3400)
during the ESTRO Forum.

Other meeting highlights

* Redesigned Flexitron remote afterloading platform will emphasize safety and
efficiency in the brachytherapy workflow, increasing the clinician's confidence
that execution of all workflow steps proceed as planned. Included in the
redesign are multiple novel advances that optimize the treatment delivery
process.  
* MOSAIQ OIS connectivity will also be demonstrated, highlighting simple
programs to migrate from legacy Siemens LANTIS systems to MOSAIQ. MOSAIQ is in
use at more than 3,000 sites, interfacing with delivery systems from a range of
providers, including Elekta, Siemens, Varian, TomoTherapy, Accuray and Brainlab.
 
* Elekta will host a lunch symposium titled "Pioneer in Cancer Care," on  April
20, from 13:15-14:30, in Room C, Lower Level. Subjects include Versa HD, VMAT,
Agility and High Dose Rate mode, and Flexitron remote afterloading platform.

Learn more at  www.elekta.com/ESTRO.   

Versa HD is not available for sale or distribution in all markets.  

For further information, please contact:  
Johan Andersson, Director, Investor Relations,  Elekta AB
Tel: +46 702 100 451, email:  johan.andersson@elekta.com    
Time zone: CET: Central European Time  

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta 
 
Tel: +1 770-670-2447, email:  michelle.joiner@elekta.com 
Time zone: ET: Eastern Time  

About Elekta  
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both healthcare providers and patients,
Elekta aims to improve, prolong and even save patient lives.   

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,400 employees globally. The
corporate headquarters is located in  Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website:  www.elekta.com. 
 

SOURCE  Elekta

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.